NOVEL 1,2-DIARYLCYCLOPENTENES ARE SELECTIVE, POTENT, AND ORALLY-ACTIVE CYCLOOXYGENASE INHIBITORS

被引:0
|
作者
REITZ, DB
LI, JJ
NORTON, MB
REINHARD, EJ
HUANG, HC
PENICK, MA
COLLINS, JT
GARLAND, DJ
SEIBERT, K
KOBOLDT, CM
GREGORY, SA
VEENHUIZEN, A
ZHANG, Y
ISAKSON, PC
机构
[1] MONSANTO CO,SEARLE RES & DEV,MED CHEM,ST LOUIS,MO 63198
[2] MONSANTO CO,SEARLE RES & DEV,INFLAMMATORY DIS RES,ST LOUIS,MO 63198
关键词
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
1,2-Diarylcyclopentenes have been shown to be very potent inhibitors of the inducible form of cyclooxygenase (COX-2) with inhibition (IC50) in the low nanomolar range and selectivity ratios as great as four orders of magnitude. In vivo testing in the rat carrageenan-induced paw edema model has established that 1,2-diarylcyclopentenes are orally active antiinflammatory agents with inhibition as high as 39% at 10 mpk. 1,2-Diarylcyclopentene sulfonamide inhibitors 2 were also found to be very potent COX-2 inhibitors, although a concomitant increase in COX-1 activity rendered these analogs less selective overall. Geminal substitution at the 4-position of 1,2-diarylcyclopentenes 1 and 2 produced methyl sulfone inhibitors 3 and sulfonamide inhibitors 4, respectively, which were also less selective due to increased COX-1 activity. Dehydration of 3 and 4a provided novel planar cyclopentadiene methyl sulfone inhibitors 5 and sulfonamide inhibitor 6a, respectively, which were found to be even less selective.
引用
收藏
页码:351 / 363
页数:13
相关论文
共 50 条
  • [31] MEDI 496-Identification of novel, orally-active inhibitors of the TRPV1 (VR1) receptor
    Wei, Zhi-Liang
    Fang, Yunfeng
    Kaub, Carl
    Janagani, Satyanarayana
    Sahasrabudhe, Kiran
    Wu, Guoxhian
    Kincaid, John
    Duncton, Matthew
    Lonergan, David
    Orike, Nina
    Ramomoorthy, Krithika
    Dourado, Michelle
    Acevedo, Alejandra
    Vincent, Fabien
    Hackos, David
    Zhang, Qingling
    Liu, Luna
    Shumilla, Jennifer
    Maruyama, Karly
    Hague, Nadia
    Brotz, Tilmann
    Emerling, Daniel
    Martin, Kathleen
    Takada, Junji
    Nakao, Kazunari
    Baba, Katsuhiro
    Nakagawa, Tetsuhiko
    Yamamura, Kenzo
    Kelly, Michael
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [32] NEW ORALLY-ACTIVE LEUKOCYTE RECRUITMENT INHIBITORS AS ANTIINFLAMMATORY AGENTS
    PERUMATTAM, J
    HAMILTON, G
    WU, JP
    CONFER, WL
    SHAO, C
    HATOUM, HN
    VENKATARAMAN, B
    BLOK, N
    YANG, XJ
    LOWE, VC
    LAEMONT, K
    ENDEMANN, G
    BRYANT, CM
    FENG, Y
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1994, 208 : 121 - MEDI
  • [33] 3-Amido-3-aryl-piperidines: A Novel Class of Potent, Selective, and Orally Active GlyT1 Inhibitors
    Pinard, Emmanuel
    Alberati, Daniela
    Alvarez-Sanchez, Ruben
    Brom, Virginie
    Burner, Serge
    Fischer, Holger
    Hauser, Nicole
    Kolczewski, Sabine
    Lengyel, Judith
    Mory, Roland
    Saladin, Christian
    Schulz-Gasch, Tanja
    Stalder, Henri
    ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (04): : 428 - 433
  • [34] CP-123, 369 A POTENT, ORALLY-ACTIVE MACROLACTONE IMMUNOSUPPRESSANT
    KOCH, K
    NEWBORG, MF
    HANSON, DC
    COOPER, K
    SHEPARD, RM
    BIEHL, MJ
    BIGGERS, MS
    SCHULTE, G
    SNYDER, JR
    FERRAINA, RA
    DONOVAN, C
    GUADIANA, MA
    KOSTEK, GJ
    SAWYER, PS
    MEISER, BM
    MELVIN, LS
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 209 : 16 - MEDI
  • [35] Phenolic thiazoles as novel orally-active neuroprotective agents
    Harnett, JJ
    Roubert, V
    Dolo, C
    Charnet, C
    Spinnewyn, B
    Cornet, S
    Rolland, A
    Marin, JG
    Bigg, D
    Chabrier, PE
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (01) : 157 - 160
  • [36] Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)
    Shakespeare, William
    Fantin, Valeria
    Wang, Frank
    Kohlmann, Anna
    Liu, Shuangying
    Huang, Wei-Sheng
    Wang, Yihan
    Zou, Dong
    Thomas, Mathew
    Li, Feng
    Qi, Jiwei
    Cai, Lisi
    Dwight, Thimothy
    Xu, Yongjin
    Xu, Rongsong
    Dodd, Rory
    Xu, Qihong
    Anjum, Rana
    Zhang, Sen
    Keats, Jeffrey
    Xue, Ling
    Wardwell, Scott
    Ning, Yaoyu
    Moran, Lauren
    Mohemmad, Qurish
    Zhu, Xiaotian
    Narasimhan, Narayana
    Rivera, Victor
    Dalgarno, David
    Clackson, Tim
    CANCER RESEARCH, 2009, 69
  • [37] Discovery of triazines as potent, selective and orally active PDE4 inhibitors
    Gewald, Rainer
    Grunwald, Christian
    Egerland, Ute
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (15) : 4308 - 4314
  • [38] ACETOHYDROXAMIC ACIDS AS POTENT, SELECTIVE, ORALLY ACTIVE 5-LIPOXYGENASE INHIBITORS
    JACKSON, WP
    ISLIP, PJ
    KNEEN, G
    PUGH, A
    WATES, PJ
    JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (03) : 499 - 500
  • [39] Pharmacokinetic and pharmacodynamic characteristics in healthy volunteers of razaxaban, an orally-active, potent, selective inhibitor of Factor Xa.
    Swaminathan, A
    Frost, C
    Knabb, R
    Bai, SA
    Kornhauser, D
    Mosqueda-Garcia, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P6 - P6
  • [40] N-3-SUBSTITUTED PYRIMIDINONES AS POTENT ORALLY-ACTIVE AT1RECEPTOR ANTAGONISTS
    SALIMBENI, A
    BRAVI, M
    CALIARI, S
    CANEVOTTI, R
    POMA, D
    RENZETTI, AR
    SCOLASTICO, C
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1993, 206 : 75 - MEDI